Monarch Partners Asset Management LLC Krystal Biotech, Inc. Transaction History
Monarch Partners Asset Management LLC
- $328 Million
- Q4 2022
A detailed history of Monarch Partners Asset Management LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Monarch Partners Asset Management LLC holds 53,905 shares of KRYS stock, worth $10.3 Million. This represents 1.3% of its overall portfolio holdings.
Number of Shares
53,905
Previous 46,494
15.94%
Holding current value
$10.3 Million
Previous $3.24 Million
31.75%
% of portfolio
1.3%
Previous 0.97%
Shares
3 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.4MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$752 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$543 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$499 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$277 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$188 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.89B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...